Discover Our Latest News
Read More about Driving Precision Medicine as the New Standard of CarePosted on March 14, 2023Driving Precision Medicine as the New Standard of CareCoriell Life Sciences is exploring new horizons for a healthier world and is driving a…Read More about Driving Precision Medicine as the New Standard of Care
Read More about New Research Finds Precision Medicine Has Reached a Global Tipping Point for AdoptionPosted on January 18, 2023New Research Finds Precision Medicine Has Reached a Global Tipping Point for AdoptionLife science leaders say the time is finally right for healthcare systems, employers, and governments…Read More about New Research Finds Precision Medicine Has Reached a Global Tipping Point for Adoption
Read More about 2023 PharmaVoice Year in Preview Featuring Coriell Life SciencesPosted on January 4, 20232023 PharmaVoice Year in Preview Featuring Coriell Life SciencesWhat’s in store for 2023? Our President & CEO, ScottMegill weighs in on how smarter…Read More about 2023 PharmaVoice Year in Preview Featuring Coriell Life Sciences
The expert and experienced speakers at Coriell Life Sciences have spoken at a wide variety of industry and related events, focusing on population health with uncompromising scientific and medical excellence as trusted, ethical, and prudent advisors. CLS continues to go beyond genetic testing to provide clinical results that are actionable, improve lives, reduce costs, and simplify decision-making.
Enterprise Pharmacogenomics (PGx)
Pharmacogenomics represents a potentially powerful enhancement to current wellness and medication risk management programs. However, challenges must be addressed to successfully implement these programs especially in large populations where the members and their prescribing physicians are naïve or misinformed to the utilization of genetics for personalized prescribing. We describe the population assessment, program implementation, outcomes from our efforts, and its relevance across poly-pharmacy and working well populations.
Turnkey Return-to-Operations Program
The CLS Return-to-Operations (RTO) Program is a turnkey solution that goes beyond testing to include complete analytics & implementation to get businesses and schools up-and-running again & prevent further widescale disruption. Our data analytics tools & testing infrastructure combine health claims, company demographics, COVID-19 progression, individualized job hazard exposure, & business priorities to provide decision support and execution employers need today.
Scott MegillPresident and Chief Executive OfficerRead More about Scott Megill
Scott Megill is President and Chief Executive Officer of Coriell Life Sciences (CLS). With a vision to translate decades of cutting-edge...
Jeffrey A. Shaman, PhD, MSChief Science OfficerRead More about Jeffrey A. Shaman, PhD, MS
Jeffrey Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences where he oversees the company’s research, education,...
Philadelphia, PAAmerican Public Health Forum (APHA) 2019
Orlando, FLPharmacy Benefit Management Institute’s (PBMI) 25th Annual National Conference
Philadelphia, PANCTR 98th Annual Conference
Philadelphia, PAPrecision Medicine Leaders Summit – Pharmacogenomics
- The Chamber Go to The Chamber website.
- Clinical Pharmacogenics Implementation Consortium Go to Clinical Pharmacogenics Implementation Consortium website.
- EHIR Go to EHIR website.
- Public Sector Healthcare Roundtable Go to Public Sector Healthcare Roundtable website.
- Personalized Medicine Coalition Go to Personalized Medicine Coalition website.
- SALGBA Go to SALGBA website.
- Pharmacogenomics Research Network Go to Pharmacogenomics Research Network website.